Treatment of Rheumatoid Arthritis With Anti ‐Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic in a Global Comparative Observational Study

Conclusion. Patients initiating tocilizumab experienced improved effectiveness and drug survival than those initiating TNFi in an observational setting. This article is protected by copyright. All rights reserved.

Source: Arthritis Care and Research - June 1, 2017 Category: Rheumatology Authors: Ernest H. Choy, Corrado Bernasconi, Maher Aassi, Jose Fernando Molina, Oscar Massimiliano Epis Tags: Original Article Source Type: research